HER2低表达乳腺癌的靶向治疗研究进展

国际肿瘤学杂志››2023,Vol. 50››Issue (4): 236-240.doi:10.3760/cma.j.cn371439-20221230-00046

HER2低表达乳腺癌的靶向治疗研究进展

朱军¹, 黄美金¹, 李媛², 刘泽刚³, 荀欣¹, 陈宏¹()

¹中国人民解放军联勤保障部队第九二〇医院肿瘤科，昆明 650032
²中国人民解放军联勤保障部队第九二〇医院老年医学科，昆明 650032
³中国人民解放军联勤保障部队第九二〇医院普通外科，昆明 650032

收稿日期:2022-12-30修回日期:2023-03-02出版日期:2023-04-08发布日期:2023-06-12
通讯作者:陈宏，Email： 976432413@qq.com
基金资助:
联勤保障部队第九二〇医院院内科技计划(2019YGC07)

Research progress on targeted therapy of breast cancer with low expression of HER2

Zhu Jun¹, Huang Meijin¹, Li Yuan², Liu Zegang³, Xun Xin¹, Chen Hong¹()

¹Department of Oncology， 920th Hospital of Joint Logistics Support Force， PLA， Kunming 650032， China
²Department of Geriatric Medicine， 920th Hospital of Joint Logistics Support Force， PLA， Kunming 650032， China
³Department of General Surgery， 920th Hospital of Joint Logistics Support Force， PLA， Kunming 650032， China

Received:2022-12-30Revised:2023-03-02Online:2023-04-08Published:2023-06-12
Contact:Chen Hong， Email： 976432413@qq.com
Supported by:
Intra-hospital Science and Technology Program of 920th Hospital of Joint Logistics Support Force(2019YGC07)

摘要/Abstract

摘要：

乳腺癌目前已成为女性发病率最高的恶性肿瘤，其中人表皮生长因子受体2（HER2）阳性乳腺癌占比15%~20%。随着抗HER2靶向药物的不断发展，HER2阳性乳腺癌的生存及预后显著获益。乳腺癌中45%~55%的患者为HER2低表达，该类患者通常不再接受抗HER2治疗。但HER2低表达乳腺癌的生物学行为和预后与HER2零表达乳腺癌之间存在显著差异，对此进行区分并采取相应治疗策略有助于改善患者预后。目前关于HER2低表达乳腺癌的靶向治疗已有诸多研究进展，为HER2低表达乳腺癌的精准化治疗提供了有益参考。

关键词:受体,erbB-2,乳腺肿瘤,分子靶向治疗

Abstract:

Breast cancer has become the malignant tumor with the highest incidence rate among women， of which human epidermal growth factor receptor 2 （HER2） positive breast cancer accounts for about 15%-20%. With the development of anti HER2 targeted drugs， the survival and prognosis of HER2 positive breast cancer has significantly benefited. About 45%-55% of breast cancer patients have low HER2 expression， and these patients usually do not receive anti HER2 treatment. However， there is a significant difference between the biological behavior and prognosis of breast cancer with low HER2 expression and breast cancer with zero HER2 expression. It is helpful to differentiate and adopt corresponding treatment strategies to improve the prognosis of patients. At present， there have been many advances in targeted therapy of breast cancer with low HER2 expression， which provides a useful reference for precision treatment of breast cancer with low HER2 expression.

Key words:Receptor,erbB-2,Breast neoplasms,Molecular targeted therapy

朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.

Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.

参考文献32

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi:10.3322/caac.21660
[2]	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.008. doi:10.3760/cma.j.issn.0253-3766.2019.01.008
[3]	Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2022, 20(6): 691-722. DOI: 10.6004/jnccn.2022.0030. doi:10.6004/jnccn.2022.0030
[4]	Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape[J]. J Clin Oncol, 2020, 38(17): 1951-1962. DOI: 10.1200/JCO.19.02488. doi:10.1200/JCO.19.02488pmid:32330069
[5]	Zhang H, Peng Y. Current biological, pathological and clinical landscape of HER2-low breast cancer[J]. Cancers (Basel), 2022, 15(1): 126. DOI: 10.3390/cancers15010126. doi:10.3390/cancers15010126
[6]	Perez J, Garrigós L, Gion M, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond[J]. Expert Opin Biol Ther, 2021, 21(7): 811-824. DOI: 10.1080/14712598.2021.1890710. doi:10.1080/14712598.2021.1890710pmid:33759669
[7]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南 2022[M]. 北京: 人民卫生出版社, 2022.
[8]	Tarantino P, Gandini S, Nicolò E, et al. Evolution of low HER2 expression between early and advanced-stage breast cancer[J]. Eur J Cancer, 2022, 163: 35-43. DOI: 10.1016/j.ejca.2021.12.022. doi:10.1016/j.ejca.2021.12.022pmid:35032815
[9]	Zhang H, Katerji H, Turner BM, et al. HER2-low breast cancers[J]. Am J Clin Pathol, 2022, 157(3): 328-336. DOI: 10.1093/ajcp/aqab117. doi:10.1093/ajcp/aqab117
[10]	Ferrando-Díez A, Felip E, Pous A, et al. Targeted therapeutic options and future perspectives for HER2-positive breast cancer[J]. Cancers (Basel), 2022, 14(14): 3305. DOI: 10.3390/cancers14143305. doi:10.3390/cancers14143305
[11]	Schettini F, Chic N, Brasó-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer[J]. NPJ Breast Cancer, 2021, 7(1): 1. DOI: 10.1038/s41523-020-00208-2. doi:10.1038/s41523-020-00208-2pmid:33397968
[12]	Mohamed M, Mohd Nafi SN, Jaafar H, et al. A retrospective hospital-based study of HMGCR expression in HER2 IHC 2+ and 3+ breast cancer[J]. Asian Pac J Cancer Prev, 2021, 22(7): 2043-2047. DOI: 10.31557/APJCP.2021.22.7.2043. doi:10.31557/APJCP.2021.22.7.2043
[13]	Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials[J]. Lancet Oncol, 2021, 22(8): 1151-1161. DOI: 10.1016/S1470-2045(21)00301-6. doi:10.1016/S1470-2045(21)00301-6pmid:34252375
[14]	Zhang G, Ren C, Li C, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status[J]. BMC Med, 2022, 20(1): 142. DOI: 10.1186/s12916-022-02346-9. doi:10.1186/s12916-022-02346-9pmid:35484593
[15]	Chumsri S, Li Z, Serie DJ, et al. Incidence of late relapses in patients with HER2-positive breast cancer receiving adjuvant trastuzumab: combined analysis of NCCTG N9831 (alliance) and NRG oncology/NSABP B-31[J]. J Clin Oncol, 2019, 37(35): 3425-3435. DOI: 10.1200/JCO.19.00443. doi:10.1200/JCO.19.00443pmid:31622131
[16]	Chumsri S, Serie DJ, Li Z, et al. Effects of age and immune landscape on outcome in HER2-positive breast cancer in the NCCTG N9831 (alliance) and NSABP B-31 (NRG) trials[J]. Clin Cancer Res, 2019, 25(14): 4422-4430. DOI: 10.1158/1078-0432.CCR-18-2206. doi:10.1158/1078-0432.CCR-18-2206pmid:30808774
[17]	Fehrenbacher L, Cecchini RS, Geyer CE Jr, et al. NSABP B-47/NRG oncology phase Ⅲ randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2[J]. J Clin Oncol, 2020, 38(5): 444-453. DOI: 10.1200/JCO.19.01455. doi:10.1200/JCO.19.01455pmid:31821109
[18]	Modi S. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: plain language summary of the DESTINY-Breast01 study[J]. Future Oncol, 2021, 17(26): 3415-3423. DOI: 10.2217/fon-2021-0427. doi:10.2217/fon-2021-0427pmid:34263665
[19]	U.S. Food & Drug Administration. FDA news release: FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies[EB/OL]. (2019-12-20)[2022-12-22]. https://www.fda.gov/news-events/press-announ-cements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available.
[20]	Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20. DOI: 10.1056/NEJMoa2203690. doi:10.1056/NEJMoa2203690
[21]	T-DXd: new standard for HER2-low breast cancer[J]. Cancer Discov, 2022, 12(8): 1828. DOI: 10.1158/2159-8290.CD-NB2022-0043. doi:10.1158/2159-8290.CD-NB2022-0043pmid:35666611
[22]	Schlam I, Tolaney SM, Tarantino P. How I treat HER2-low advanced breast cancer[J]. Breast, 2023, 67: 116-123. DOI: 10. 1016/j.breast.2023.01.005. doi:10. 1016/j.breast.2023.01.005
[23]	Tarantino P, Curigliano G, Tolaney SM. Navigating the HER2-low paradigm in breast oncology: new standards, future horizons[J]. Cancer Discov, 2022, 12(9): 2026-2030. DOI: 10.1158/2159-8290.CD-22-0703. doi:10.1158/2159-8290.CD-22-0703
[24]	U.S. Food & Drug Administration. FDA news release: FDA approves first targeted therapy for HER2-low breast cancer[EB/OL]. (2022-08-05)[2022-09-07]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-her2-low-breast-cancer.
[25]	Li H, Zhang X, Xu Z, et al. Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors[J]. Antib Ther, 2021, 4(3): 175-184. DOI: 10.1093/abt/tbab017. doi:10.1093/abt/tbab017pmid:34532642
[26]	Jiang Z, Sun T, Wang X, et al. A multiple center, open-label, single-arm, phase Ⅱ clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer[J]. J Clin Oncol, 2022, 40(16_suppl): 1102. DOI: 10.1200/JCO.2022.40.16_suppl.1102. doi:10.1200/JCO.2022.40.16_suppl.1102
[27]	Banerji U, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study[J]. Lancet Oncol, 2019, 20(8): 1124-1135. DOI: 10.1016/S1470-2045(19)30328-6. doi:S1470-2045(19)30328-6pmid:31257177
[28]	Saura C, Thistlethwaite F, Banerji U, et al. A phase Ⅰ expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer[J]. J Clin Oncol, 2018, 36(15_suppl): 1014. DOI: 10.1200/JCO.2018.36.15_suppl.1014. doi:10.1200/JCO.2018.36.15_suppl.1014
[29]	Xu B, Wang J, Fang J, et al. Abstract PD4-06: early clinical development of RC48-ADC in patients with HER2 positive metastatic breast cancer[J]. Cancer Res, 2020, 80(4_Supplement): PD4-06. DOI: 10.1158/1538-7445.SABCS19-PD4-06. doi:10.1158/1538-7445.SABCS19-PD4-06
[30]	Wang J, Liu Y, Zhang Q, et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies[J]. J Clin Oncol, 2021, 39(15_suppl): 1022. DOI: 10.1200/JCO.2021.39.15_suppl.1022. doi:10.1200/JCO.2021.39.15_suppl.1022
[31]	Bergstrom D, Bodyak N, Park P, et al. Abstract P4-14-28: XMT-1522 induces tumor regressions in preclinical models representing HER2 positive and HER2 low expressing breast cancer[J]. Cancer Res, 2016, 76 (4_Supplement): P4-14-28. DOI: 10.1158/1538-7445.SABCS15-P4-14-28. doi:10.1158/1538-7445.SABCS15-P4-14-28
[32]	Hamilton EP, Barve MA, Bardia A, et al. Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors[J]. J Clin Oncol, 2018, 36(15_suppl): 2546. DOI: 10.1200/JCO.2018.36.15_suppl.2546. doi:10.1200/JCO.2018.36.15_suppl.2546